TITLE

What Happened to Drug Trials in Ulcerative Colitis? Problems, PPARs, Placebos, and (Possible) Progress

AUTHOR(S)
Kornbluth, Asher
PUB. DATE
December 2001
SOURCE
American Journal of Gastroenterology;Dec2001, Vol. 96 Issue 12, p3232
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Focuses on the decline in drug trials for ulcerative colitis (UC). Several strategic business factors in the decline in drugs trials for UC; Results of a clinical trial on rosaglitazone; Meta-analysis of placebo-treated patients in UC trials; Outlook for drug trial in UC.
ACCESSION #
17611766

 

Related Articles

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...

  • Recent Indications and Methods of Surgery for Inflammatory Bowel Disease. S. Ohki; S. Terashima; K. Sekikawa; S. Takenoshita; M. Gotoh // Current Drug Targets - Inflammation & Allergy;Jun2003, Vol. 2 Issue 2, p113 

    Inflammatory bowel disease, notably ulcerative colitis (UC) or Crohn disease (CD), is basically benign, but sometimes develops into serious or fatal cancer. While the primary therapies are medical, such as pharmacotherapy and dietetic modification, intractable, serious, and cancerous cases can...

  • What's new in inflammatory bowel disease in 2008? Baumgart, Daniel C. // World Journal of Gastroenterology;1/21/2008, Vol. 14 Issue 3, p329 

    Ulcerative colitis and Crohn's disease represent the two major forms of inflammatory bowel disease. In this highlight topic series of articles we cover the latest developments in genetics and epidemiology, intestinal physiology, mucosal immunology, mechanisms of epithelial cell injury and...

  • Ulcerative colitis. Ghosh, Subrata // BMJ: British Medical Journal (International Edition);04/22/2000, Vol. 320 Issue 7242, p1119 

    Provides information on ulcerative colitis. Clinical features and diagnosis; Etiology; Clinical management; Failure of medical management and its indications for surgery.

  • PREVALENCE AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DATA FROM PRIMARY CARE RECORDS, INCLUDING 5-ASA PRESCRIBING AND COMPLIANCE. Stone, M.A.; Mayberry, J.F.; Baker, R.B. // Gut;Apr2003 Supplement 1, Vol. 52, pA68 

    Background: Data from general practice (GP) records in North Tees (Rubin et al, 2000) suggested a higher prevalence of inflammatory bowel disease (IBD) than previous estimates from hospital data. Regular prescribing of 5-aminosalicylic acid (5-ASA) therapy can reduce the risk of colorectal...

  • Ulcerative Colitis.  // Current Medical Literature: Gastroenterology;2008, Vol. 27 Issue 3, p87 

    The article discusses several studies on ulcerative Colitis. In "Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis," the authors analyzed factors that might predict which patients are likely to respond to such rescue treatment. In another study...

  • Mesalamine Capsules for Treatment of Active Ulcerative Colitis: Results of a Controlled Trial. Hanauer, Stephen; Schwartz, Jerrold; Robinson, Malcolm; Roufail, Walter; Arora, Sanjeev; Cello, John; Safdi, Michael // American Journal of Gastroenterology;Aug1993, Vol. 88 Issue 8, p1188 

    The efficacy of a capsule formulation of mesalamine was assessed in 374 patients with mild to moderately active ulcerative colitis. Patients, stratified to pancolitis or left-sided disease, received either placebo or mesalamine at 1, 2, or 4 g daily for 8 wk. Efficacy was assessed using clinical...

  • A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. van Deventer, S. J. H.; Tami, J. A.; Wedel, M. K. // Gut;Dec2004, Vol. 53 Issue 12, p1646 

    Objective: To evaluate the safely and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule, after 1, 3, and 6 months. Methods: This was a randomised, placebo controlled, double blind, escalating dose multicentre study in 40 patients with mild...

  • A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Ogata, H.; Matsui, T.; Nakamura, M.; Lida, M.; Takazoe, M.; Suzuki, Y.; Hibi, T. // Gut;Sep2006, Vol. 55 Issue 9, p1255 

    Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics